RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
James Dignam
No relevant relationships to disclose
Minhee Won
No relevant relationships to disclose
Deborah T. Blumenthal
No relevant relationships to disclose
Michael A. Vogelbaum
Honoraria - Merck
Kenneth D. Aldape
No relevant relationships to disclose
Howard Colman
Consultant or Advisory Role - Castle Biosciences; Roche/Genentech
Arnab Chakravarti
No relevant relationships to disclose
Robert Jeraj
No relevant relationships to disclose
Terri S. Armstrong
Research Funding - Genentech
Jeffrey Scott Wefel
Consultant or Advisory Role - Roche/Genentech
Paul D. Brown
No relevant relationships to disclose
Kurt A. Jaeckle
No relevant relationships to disclose
David Schiff
Consultant or Advisory Role - Genentech
James Norman Atkins
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
Maria Werner-Wasik
No relevant relationships to disclose
Ritsuko Komaki
No relevant relationships to disclose
Erik P. Sulman
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Merck
Minesh P. Mehta
Consultant or Advisory Role - Genentech; Merck
Stock Ownership - Accuray
Honoraria - Merck